Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPT-005
- Development stage
- Preclinical
- Lead developer
- Tenpoint Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Sub-retinal
01
Overview
TPT-005 is an allogenic cell suspension therapy composed of retinal pigment epithelium (RPE) cells derived from human embryonic stem cells. These RPE cells are differentiated and expanded in vitro to closely resemble endogenous RPE cells in function, morphology, markers, and pigmentation profile. The therapy is designed as a first-in-class cell therapy for restoring vision in patients affected by geographic atrophy (GA), a late stage of macular degeneration that leads to permanent central vision loss. TPT-005 aims to replace lost or damaged RPE cells via sub-retinal injection, potentially offering a durable and curative solution by restoring healthy RPE function where natural regeneration does not occur.
Beyond the preview
Go deeper on TPT-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPT-005.